

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Grillo-Lopez.)	Examiner: Gary B. Nickol
)	
)	
Serial No:	09/840,872)	Art Unit: 1642
)	
Filed:	April 25, 2001)	
)	
Title:	INTRATHECAL)	
	ADMINISTRATION OF)	
	RITUXIMAB FOR TREATMENT)	
	OF CENTRAL NERVOUS)	
	SYSTEM LYMPHOMAS)	
)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the information on the attached Form PTO-1449 be considered by the Office during the pendency of the above-entitled application, pursuant to 37 C.F.R. 1.97. In accordance with 37 C.F.R. 1.97(h), the filing of the Information Disclosure Statement shall not constitute an admission that any information cited therein is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b). In the interest of full and complete disclosure to the Office, some or all of the art cited herein may not be considered by Applicant(s) or the Undersigned to be material under the standards of materiality defined in C.F.R. 1.56(b), enacted March 16, 1992, as amended September 8, 2000, and may merely be technical background which may be of interest to the Examiner.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

The Commissioner is hereby authorized to charge any such fee, including any fee due with this submission, if the attached check(s) is in the wrong amount or otherwise improper or missing, in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 03-3975, Order No. 037003-0280609.

Respectfully submitted,

Date: September 5, 2003



Suzanne L. Biggs
Registration No. 30,158 for
Direct Line: (858) 509-4095

Thomas A. Cawley, Jr.
Registration No. 40,944
PILLSBURY WINTHROP LLP
1600 Tysons Boulevard
McLean, VA 22102
Telephone: (703) 905-2000
Fax Line: (703) 905-2500

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
	037003-0280609	

2000-30-0154A

Applicant: Grillo-Lopez

Appln. No.: 09/840,872

Filing Date: April 25, 2001

Date: September 5, 2003

Page

1 of

6

Examiner: Gary B. Nickol

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class.	Filing Date (if appropriate)
AR	4,348,376	09/1982	Goldenberg	424	1	
BR	4,454,106	06/1984	Gansow, et al.	424	1.1	
CR	4,460,559	07/1984	Goldenberg	424	1.1	
DR	4,472,509	09/1984	Gansow, et al.	436	548	
ER	4,665,077	05/1987	Stringfellow, et al.	514	269	
FR	4,816,567	03/1989	Cabilly, et al.	530	387	
GR	4,831,175	05/1989	Gansow, et al.	558	17	
HR	5,114,721	05/1992	Cohen, et al.	424	534	
IR	5,116,964	05/1992	Capon, et al.	536	27	
JR	5,182,107	01/1993	Friden	424	85.91	
KR	5,500,362	03/1996	Robinson, et al.	435	7.23	
LR	5,595,721	01/1997	Kaminski, et al.	424	1.49	
MR	5,674,492	10/1997	Armitage, et al.	424	144.1	
NR	5,677,180	10/1997	Robinson, et al.	435	328	
OR	5,693,780	12/1997	Newman, et al.	536	23.53	
PR	5,736,137	04/1998	Anderson, et al.	424	133.1	
QR	5,747,037	05/1998	Noelle, et al.	424	154.1	
RR	5,776,456	07/1998	Anderson, et al.	424	133.1	
SR	5,801,227	09/1998	Fanslow, III et al.	530	388.73	
TR	5,821,337	10/1998	Carter, et al.	530	387.3	
UR	5,833,987	11/1998	Noelle, et al.	424	154.1	
VR	5,843,398	12/1998	Kaminski, et al.	424	1.49	
WR	5,843,439	12/1998	Anderson, et al.	424	133.1	
XR	5,874,082	02/1999	de Boer	424	153.1	
YR	5,874,085	02/1999	Mond, et al.	424	195.11	
ZR	5,876,718	03/1999	Noelle, et al.	424	154.1	
AAR	5,716,614	02/1998	Katz, et al.	424	94.3	
BBR	6,001,358	12/1999	Black, et al.	424	154.1	

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
CCR	0 340 109 B1	05/1997	EP	Steinman, et al.				
DDR	0 404,097 B1	09/1996	EP	Bosslet, et al.				
EER	0 555 880 A2	08/1993	EP	Aruffo, et al.				

	FFR	0 555 880 A3	08/1993	EP	Aruffo, et al.				
	GGR	WO 90/08187	07/1990	WO	Reinherz, et al.				
	HHR	WO 90/11294	10/1990	WO	Howell, et al.				
	IIR	WO 91/01133	02/1991	WO	Goldstein, et al.				
	JJR	WO 93/11161	06/1993	WO	Whitlow, et al.				
	KKR	WO 94/11026	05/1994	WO	Anderson, et al.				
	LLR	WO 95/06666	03/1995	WO	Noelle, et al.				
	MMR	WO 95/17202	06/1995	WO	Armitage, et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

NNR	Abrey et al., Combination chemotherapy in primary central nervous system lymphoma," (abstract) <i>Proc. Am. Soc. Clin. Onc.</i> (1999)				
OOR	Abrey et al., Long-term survival in primary CNS lymphoma, <i>J. Clin. Oncol.</i> 16: 859-63 (1998)				
PPR	Armitage et al., Molecular and biological characterization of a murine ligand for CD40, <i>Nature</i> 357:80-82 (1992)				
QQR	Behr et al., Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, <i>Clin. Cancer Res.</i> 5: 3304s-14s (1999)				
RRR	Bejcek et al., Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen, <i>Cancer Res.</i> 55: 2346-51 (1995)				
SSR	Benoit et al., Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin, <i>Immunopharmacology</i> 35: 129-139 (1996)				
TTR	Berinstein et al., Association of serum rituximab (IDE-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, <i>Ann. Oncol.</i> 9: 995-1001 (1998)				
UUR	Blay et al., High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series, <i>J. Clin. Oncol.</i> 16: 864-871 (1998)				
VVR	Bolognesi et al., Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): <i>in vitro</i> and <i>in vivo</i> studies, <i>Br. J. Haematol.</i> 101: 179-88 (1998)				
WWR	Capon et al., Designing CD4 immunoadhesins for AIDS therapy, <i>Nature</i> 337: 525-531 (1989)				
XXR	Chamberlain et al., Primary central nervous system lymphoma: a role for adjuvant chemotherapy, <i>J. Neuro. Oncol.</i> 14: 271-275 (1992)				
YYR	Cheng et al., Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma, <i>Cancer</i> 82: 1946-51 (1998)				
ZZR	Clodi et al., Unbalanced expression of Fas and CD40 in mantle cell lymphoma, <i>Brit. J. Haematol.</i> 103: 217-9 (1998)				
AAAR	Clynes et al., Fc receptors are required in passive and active immunity to melanoma, <i>PNAS (USA)</i> 95:652-656 (1998)				
BBBR	Coiffier et al., Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study, <i>Blood</i> 92: 1927-1932 (1998)				
CCCR	Czuczman et al., Treatment of patients with low-grade B-cell lymphoma with the combinations of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, <i>J. Clin. Oncol.</i> 17: 268-76 (1999)				
DDDR	DeAngelis et al., "Primary Central Nervous System Lymphoma," IN <i>CANCER: PRINCIPLES & PRACTICE OF ONCOLOGY</i> 2233-2242 (DeVita et al., eds. 1997).				

	EEER	Deguchi <i>et al.</i> , Retention of biologic activity of human epidermal growth factor following conjugation of a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker, <u>Bioconjug. Chem.</u> 10: 32-37 (1999)			
	FFFR	Endo, <u>Gan To Kagaku Ryoho</u> 26: 744-748 (1999)			
	GGG	Fine <i>et al.</i> , Primary central nervous system lymphoma, <u>Annals Intern. Med.</u> 119: 1093-1104 (1993)			
	HHHR	Flavell <i>et al.</i> , Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone, <u>Int. J. Cancer</u> 62: 337-44 (1995)			
	IIIR	Freilich <i>et al.</i> , Chemotherapy without radiation therapy as initial. Treatment for primary CNS lymphoma in older patients, <u>Neurology</u> 46: 435-439 (1996)			
	JJJR	Funakoshi <i>et al.</i> , Inhibition of human B-cell lymphoma growth by CD40 stimulation, <u>Blood</u> 83: 2787-2794 (1994)			
	KKKR	Funakoshi <i>et al.</i> , Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas, <u>J. Immunother. Emphasis Tumor Immunol.</u> 19: 93-101 (1996)			
	LLLR	Ghetie <i>et al.</i> , Anti-CD19 antibodies inhibit the function of the P-gp pump in multigrug-resistant B lymphoma cells, <u>Clin. Cancer Res.</u> 5: 3920-7 (1999)			
	MMMR	Green <i>et al.</i> , Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS, <u>Virology</u> 241: 260-268 (1998)			
	NNNR	Gruss <i>et al.</i> , CD40/CD40 ligand interactions in normal, reactive and malignant lymphohematopoietic tissues, <u>Leuk. Lymphoma</u> 24: 393-422 (1997)			
	OOO	Hekman <i>et al.</i> , Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody <u>Cancer Immunol. Immunother.</u> 32:364-372 (1991)			
	PPPR	Herrlinger <i>et al.</i> , Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin, <u>J. Neurooncol.</u> 40: 1-9 (1998)			
	QQQ	Hollenbaugh <i>et al.</i> , The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, <u>EMBO J.</u> 11:4313-4321 (1992)			
	RRRR	Hollinger <i>et al.</i> , "Diabodies": small bivalent and bispecific antibody fragments, <u>Proc. Nad. Acad. Sci. USA</u> 90:6444.-6448 (1993).			
	SSSR	Huwylter <i>et al.</i> , Brain drug delivery of small molecules using immunoliposomes, <u>Proc. Nat'l Acad. Sci. USA</u> 93: 14164-14169 (1996)			
	TTTR	Illidge <i>et al.</i> , The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma, <u>Blood</u> 94: 233-43 (1999)			
	UUUR	Janeway, Immunotherapy by peptides, <u>Nature</u> , 341: 482 (1989)			
	VVVR	Johnson <i>et al.</i> , Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system, <u>Blood</u> 82: 1848-1857 (1993)			
	WWWW	Kiesel <i>et al.</i> , Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytosis, <u>Leukemia Research</u> 11, 12: 1119 (1987)			

	XXXR	Kramer <i>et al.</i> , Tc-99m LL-2 Fab' monoclonal antibody imaging in acquired immune deficiency syndrome-related lymphoma, <u>Cancer</u> 80: 2469-2477 (1997)			
	YYYR	Kroll <i>et al.</i> , Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means, <u>Neurosurgery</u> 42: 1083-99 (1998)			
	ZZZL	Ledbetter <i>et al.</i> , Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency, <u>Circ. Shock</u> 44: 67-72 (1994)			
	AAAA	Lederman <i>et al.</i> , Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), <u>J. Exp. Med.</u> 175: 1091-1101 (1992)			
	BBBB	Leget <i>et al.</i> , Use of rituximab, the new FDA-approved antibody, <u>Curr. Opin. Oncol.</u> 10: 548-551 (1998)			
	CCCC	Lesser <i>et al.</i> , The chemotherapy of adult primary brain tumor, <u>Cancer Treat. Rev.</u> 19: 261-281 (1993)			
	DDDD	Li <i>et al.</i> , Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy, <u>Cancer Immunol. Immunother.</u> 47: 121-30 (1998)			
	EEEE	Lieberman <i>et al.</i> , Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion, <u>J. Neurosurg.</u> 82: 1021-1029 (1995)			
	FFFF	Linsley <i>et al.</i> , Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, <u>J. Exp. Med.</u> 178: 721-730 (1991)			
	GGG	Maloney <i>et al.</i> , IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, <u>Blood</u> 90: 2188-2195 (1997)			
	HHHH	Mansfield <i>et al.</i> , Characterization of RFB4-pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies, <u>Bioconjug. Chem.</u> 7: 557-63 (1996)			
	IIIR	Mason <i>et al.</i> , ¹¹¹ Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases, <u>Neurology</u> 50: 438-444 (1998)			
	JJJJR	McLaughlin <i>et al.</i> , Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program, <u>J. Clin. Oncol.</u> 16: 2825-2833 (1998)			
	KKKK	McLaughlin <i>et al.</i> , Clinical status and optimal use of rituximab for B-cell lymphomas, <u>Oncology (Huntingt)</u> 12: 1763-1777 (1998)			
	LLLL	Monjour <i>et al.</i> , Lymphomes malins non Hodgkiens primitifs du système nerveux central, <u>Rev. Neurol. (Paris)</u> 148: 589-600 (1992)			
	MMMF	Morrison <i>et al.</i> , Genetically engineered antibody molecules, <u>Adv. Immunol.</u> 44: 65-92 (1988)			
	NNNN	Morrison <i>et al.</i> , Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <u>Proc. Natl. Acad. Sci. USA</u> , 81:6851-6855 (1984)			
	OOO	Murphy <i>et al.</i> , Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes, <u>Blood</u> 86: 1946-1953 (1995)			
	PPPP	Nguyen <i>et al.</i> , IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients, <u>Eur. J. Haematol.</u> 62: 76-82 (1999)			

	QQQ	Offner <i>et al.</i> , T Cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis, <u>Science</u> 251: 430-432 (1991)			
	RRR	O'Neill <i>et al.</i> , Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy?, <u>Int'l J. Radiation Oncol. Biol. Phys.</u> 33: 663-673 (1995)			
	SSS	Orlowski <i>et al.</i> , Hodgkin's disease with leptomeningeal involvement, <u>Cancer</u> 53: 1833-1835 (1984)			
	TTT	Padlan, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, <u>Molec. Immun.</u> 28: 489-498 (1991)			
	UUU	Padlan, Anatomy of the antibody molecule, <u>Molec. Immun.</u> 31: 169-217 (1994)			
	VVV	Partridge <i>et al.</i> , Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, <u>Pharm. Res.</u> 15: 576-82 (1998)			
	WWW	Pastan <i>et al.</i> , Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model, <u>Proc. Nat'l Acad. Sci. USA</u> 92: 2765-2769 (1995)			
	XXXX	Perez-Jaffe <i>et al.</i> , Cerebral spinal fluid involvement by Hodgkin's disease diagnosed by CSF cytology and immunocytochemistry, <u>Diagn. Cytopathol.</u> 20:219-223 (1999)			
	YYYY	Piro <i>et al.</i> , Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma, <u>Ann. Oncol.</u> 10: 655-61 (1999)			
	ZZZ	Press <i>et al.</i> , Monoclonal antibody 1F2 (Anti-CD20) serotherapy of human B cell lymphomas, <u>Blood</u> 69: 584-591 (1987)			
	AAA	Ravetch and Kinet, Fc receptors, <u>Annu. Rev. Immunol.</u> 9:457-92 (1991)			
	BBB	Reni <i>et al.</i> , Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature, <u>Ann. Oncol.</u> 8: 227-234 (1997)			
	CCC	Sandor <i>et al.</i> , Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma, <u>J. Clin. Oncol.</u> 16: 3000-3006 (1998)			
	DDD	Schabet <i>et al.</i> , Diagnose und therapie der meningosis neoplastica, <u>Nervenarzt</u> 63: 317-27 (1992)			
	EEE	Stamenkovic <i>et al.</i> , A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas, <u>EMBO J.</u> 8: 1403-1410 (1989)			
	FFF	Stone <i>et al.</i> , A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma, <u>Blood</u> 88: 1188-97 (1996)			
	GGG	Strauchen <i>et al.</i> , Chemotherapy in the management of intraocular lymphoma, <u>Cancer</u> 63: 1918-21 (1989)			
	HHH	Tutt <i>et al.</i> , Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors, <u>J. Immunol.</u> 161: 3176-3185 (1998)			
	IIIR	Valentine <i>et al.</i> , B3.9 Structure and function of the B-cell specific 35-37 kDa CD20 protein, In: <i>Leukocyte Typing III</i> (McMichael, Ed., p. 440, Oxford University Press (1987)			

JJJJJ	Valle <i>et al.</i> , Activation of human B lymphocytes through CD40 and interleukin 4, <u>Eur. J. Immunol.</u> 19: 1463-1467 (1989)			
KKKK	Valluri <i>et al.</i> , Combination treatment of intraocular lymphoma, <u>Retina</u> 15: 125-9 (1995)			
LLLL	van Besien <i>et al.</i> , Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma, <u>Blood</u> 91: 1178-1184 (1998)			
MMM	Verhoeven <i>et al.</i> , Reshaping human antibodies: Grafting an anti-lysozyme activity, <u>Science</u> 239: 1534-1536 (1988)			
NNNN	Vlasveld <i>et al.</i> , Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19, <u>Cancer Immunol. Immunother.</u> 40:37-47(1995)			
OOO	Wang <i>et al.</i> , Induction of bcl-x by CD40 engagement rescues sIg-induced apoptosis in murine B cells, <u>J. Immunol.</u> 155: 3722-5 (1995)			
PPPP	White <i>et al.</i> , Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma, <u>Pharm. Sci. Technol. Today</u> 2: 95-101 (1999)			
QQQ	Wu <i>et al.</i> , Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody, <u>Drug. Metabol. Dispos.</u> 26: 937-9 (1998)			
RRRR	Youle, Immunotoxins for central nervous system malignancy, <u>Semin. Cancer Biol.</u> 7: 65-70 (1996)			
SSSS				
TTTT				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.